Companies/Bruker Corporation

Company profile

Bruker Corporation

NASDAQ: BRKR · Healthcare · Medical - Devices

PublicHQ Billerica, MACIK 0001109354Reports USD

#74 of 1,394 Healthcare companies by revenue45th-percentile growth

EA Score

77B+

FH 70DQ 90GM 64SS 91

v0.1 · 65/100 weight · provisional

↑ disclosure history, market scale · ↓ revenue growth (YoY), Piotroski F

Methodology →

Revenue TTM

$3.5B

Rev growth YoY (TTM)

+0.4%

Net income (FY)

-$8.6M

Employees

11,396

Market cap

$9.4B

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Revenue$3.4B$3.4B2025

Net income-$8.6M-$8.6M2025

Operating income$68.2M$68.2M2025

Total assets$6.2B$6.2B2025

Liabilities$3.7B$3.7B2025

Equity$2.5B$2.5B2025

Revenue trend

FY2019 – FY2025 · USD

$521.1M

FY19

$2.1B

FY19

$2.0B

FY20

$2.4B

FY21

$2.5B

FY22

$3.0B

FY23

$3.4B

FY24

$3.4B

FY25

Revenue by segment

Filed disclosures · FY2025

By product

Product81%

Product and Service, Other19%

By geography

Europe Excluding Germany28%

UNITED STATES26%

Asia Pacific Excluding China16%

CHINA14%

GERMANY9%

Other Country8%

The read

Bruker Corporation booked $3.4B in FY2025 revenue, growing 2.1% year over year — about the middle of the pack among Healthcare companies we track, at a -0.3% net margin.

Peers · Healthcare

Halozyme Therapeutics, Inc.85A Kymera Therapeutics, Inc.52D Nuvalent, Inc.——Corcept Therapeutics Incorporated84B+

Key facts

CEOFrank H. Laukien

SectorHealthcare

IndustryMedical - Devices

HeadquartersBillerica, MA

ExchangeNASDAQ: BRKR

Employees11,396

IPO date2000-08-04

Latest filings

8-K2026-05-21 8-K2026-05-15 10-Q2026-05-07 8-K2026-05-06 8-K2026-04-28 8-K2026-04-10 DEF 14A2026-04-10 8-K2026-04-01

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.